Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

Journal of Viral Hepatitis

Volumn 22, Issue 5, 2015, Pages 469-480

  Bruno, S ^a   Bollani, S ^a   Zignego, A L ^b   Pascasio, J M ^c   Magni, C ^d   Ciancio, A ^e   Caremani, M ^f   Mangia, A ^g   Marenco, S ^h   Piovesan, S ⁱ   Chemello, L ⁱ   Babudieri, S ^j   Moretti, A ^k   Gea, F ^l   Colletta, C ^m   Perez Alvarez, R ⁿ   Forns, X ^o   Larrubia, J R ^p   Arenas, J ^q   Crespo, J ^r   Calvaruso, V ^s   Ceccherini Silberstein, F ^t   Maisonneuve, P ^u   Craxi A ^s   Calleja, J L ^v   Di Marco, V ^w   Monti, M ^w   Rizzardini, G ^w   Landonio, S ^w   Rizzetto, M ^w   Lapini, L E ^w   Piazzolla, V ^w   Picciotto, A ^w   Alberti, A ^w   Cavaletto, L ^w   Koch, M ^w   Massari, M ^w   Muratori, L ^w   Cipriano, V ^w   Montineri, A ^w   Iacobello, C ^w   Fangazio, S ^w   Pirisi, M ^w   Colombo, A ^w   Bellati, G ^w   Mazzotta, F ^w   Pierotti, P ^w   Traverso, A ^w   Serviddio, G ^w   Russello, M ^w   Santantonio, T ^w   Drenaggi, D ^w   Marchionne, E ^w   Zuin, M ^w   Delliponti, M ^w   Farina, F ^w   Andreone, P ^w   Scuteri, A ^w   Galli, M ^w   Giannini, E G ^w   Nerli, A ^w   Carbonai, S ^w   Coppola, N ^w   Montalbano, M ^w   Portelli, V ^w   Di Biagio, A ^w   Nicolini, L A ^w   Mastroianni, C ^w   Madonia, S ^w   Licata, A ^w   Montalto, G ^w   Giannitrapani, L ^w   Mondelli, M ^w   Pellicelli, A ^w   Toniutto, P ^w   Borgia, G ^w   Gentile, I ^w   De Luca, M ^w   Di Costanzo, G G ^w   Corti, G ^w   Sousa, M ^x   Delgado, M B ^x   De La Revilla, J ^x   Navarro, J M ^x   Barcena, R ^x   Romero Gomez, M ^x   Fernandez Rodriguez, C M ^x   Narvaez, I ^x   Erdozain, J C ^x   Molina, E ^x   Fernandez, I ^x   Cuenca, B ^x   Planas, R ^x   Garcia Samaniego, J ^x   Ladero, J M ^x   Gonzalez, J M ^x   Serra, M A ^x   Castellote, I ^x   Sola, R ^x   Anton, T ^x   Ryan, I ^x   Gonzalez, F ^x   Martinez, E ^x   Portu, J ^x   more..

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d AO L Sacco   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f Ospedale di Arezzo   (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j UNIVERSITY OF SASSARI   (Italy)

^k AOS Filippo Neri   (Italy)

^l HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^m COQ Ospedale Madonna del Popolo ^*  (Italy)

ⁿ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^o HOSPITAL CLÍNIC   (Spain)

^p HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^q HOSPITAL DONOSTIA   (Spain)

^r HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^s UNIVERSITY OF PALERMO   (Italy)

^t UNIVERSITY OF ROME TOR VERGATA   (Italy)

^u EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^v HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^w V Cento ^*  (Italy)

^x V Cento   (Spain)

more..

Author keywords

boceprevir; cirrhosis; first generation protease inhibitors; hepatitis C; IFN based therapy

Indexed keywords

ALBUMIN; BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BONE MARROW TOXICITY; CHILD PUGH SCORE; DECOMPENSATED LIVER CIRRHOSIS; DRUG FATALITY; ESOPHAGUS VARICES; FEMALE; GASTROINTESTINAL TOXICITY; GENDER; HEALTH PROGRAM; HEPATITIS C; HUMAN; HUMAN TISSUE; INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROTOXICITY; NEUTROPENIA; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; RISK BENEFIT ANALYSIS; SKIN TOXICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION; AGED; ANALOGS AND DERIVATIVES; BLOOD; DRUG COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; ITALY; PROCEDURES; SPAIN; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ITALY; MALE; MIDDLE AGED; PROLINE; RIBAVIRIN; RNA, VIRAL; SPAIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84926515857     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12342     Document Type: Article

References (28)

1. Bourlière M, Wendt A, Fontaine H, et al,. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int 2013; 33 (Suppl 1): 46-55.
2. Chung RT, Baumert TF,. Curing chronic hepatitis C- The arc of a medical triumph. N Engl J Med 2014; 370: 1576-1578.
3. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
4. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
6. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
7. Manns MP, Vierling JM, Bacon BR, et al,. The combination of MK-5172, Peginterferon, and Ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014; 147: 366-376 Epub ahed of print.
8. Afdahl N, Reddy KR, Nelson DR, et al,. Ledispavir and Sofosvubir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
9. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-222.
10. Poordad F, Hezode C, Trinh R, et al,. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982 Epub ahead of print.
11. Zeuzem S, Soriano V, Asselah T, et al,. Faldaprevir and Deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639.
12. Lok AS, Gardiner DF, Hezode C, et al,. Randomized trial of daclatasvir and asunaprevir with or without Peg/IFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490-499.
13. Vierling J, Davis M, Flamm S, et al,. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with Boceprevir (BOC) + PR: the Provide study interim results. Gastroenterology 2012; 142: Supplement 1 -S-931.
14. Vierling JM, Davis M, Flamm S, et al,. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol 2014; 60: 748-756.
15. Vierling JM, Zeuzem S, Poordad F, et al,. Safety & efficacy of Boceprevir/Peginterferon/Ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol 2014; 61: 200-209 Epub ahead of print.
16. Hézode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-441.
17. Hezode C, Fontaine H, Dorival C, et al,. Effectiveness of Telaprevir or Boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142 Epub ahead of print.
18. Bruno S, Vierling JM, Esteban R, et al,. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013; 58: 479-487.
19. Iacobellis A, Siciliano M, Annicchiarico BE, et al,. Sustained virological responses following standard antiviral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009; 30: 146-153.
20. Fevery B, Susser S, Lenz O, et al,. HCV-RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy. Antivir Ther 2014; doi: 10.3851/IMP2760 Epub ahead of print.
21. Ogawa E, Furusyo N, Murata M, et al,. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. Antiviral Res 2013; 99: 119-124.
22. Foucher J, Chanteloup E, Vergniol J, et al,. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-408.
23. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
24. Cento V, Landonio S, De Luca F, et al,. A boceprevir failure in a patient infected with HCV-genotype 1 g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy. Antivir Ther 2013; 18 (4): 645-648.
25. Bruno S, Stroffolini T, Colombo M, et al,. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
26. Aleman S, Rahbin N, Weiland O, et al,. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57: 230-236.
27. Van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
28. Vergniol J, Foucher J, Terrebonne E, et al,. Non invasive test for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-1979.